Assessment of the Role of Everolimus Therapy in Patients with Renal Cell Carcinoma Based on Daily Routine and Recent Research Results

Everolimus is indicated for adults with metastatic renal cell carcinoma (mRCC) after failure of vascular endothelial growth factor receptor-tyrosine kinase inhibitors (TKI). Currently, the therapeutic applicability of EVE has been changing. Multicenter evaluation of efficacy and safety of everolimus in daily routine and definition of patient characteristics with favorable outcome. Data of 165 patients from 9 oncology institutes in Hungary were analyzed retrospectively. Everolimus therapy was used after one TKI in 10 mg starting dose. Physical and laboratory examinations and imaging tests were performed monthly and every 3 months, respectively. Median progression-free survival (PFS) was 5.4 months. Median overall survival (OS) was 16.2 months. PFS and OS results were more favorable in patients with ECOG 0-1 (p PFS  = 0.033, p OS  = 0.008) and after >9 months of TKI therapy (p PFS  = 0.019, p OS  = 0.045). Survival was longer in nonanemic patients with ECOG 0-1 than in anemic patients with ECOG 2-3, 30.9 and 7.7 months, respectively (p = 0.029). Dose reduction and treatment delay was required in 6.2% and 8.9% of patients, respectively. Common adverse events were exanthema, edema, stomatitis, anemia, and abnormal kidney functions and glucose levels. Results of this study show that everolimus is safe and efficacious in a real-world setting. Everyday practice showed that nonanemic patients with good performance status receiving TKI therapy for >9 months are favorable candidates for this treatment. Despite the efficiency of novel, registered drugs, everolimus still plays an important role during and after second-line therapy for mRCC when availability of modern remedies is limited.

Pathology oncology research : POR. 2017 Oct 13 [Epub ahead of print]

Anikó Maráz, András Csejtei, Judit Kocsis, Miklós Szűcs, Zsuzsanna Kahán, György Bodoky, Magdolna Dank, László Mangel, János Révész, Zoltán Varga, Lajos Géczi

Department of Oncotherapy, University of Szeged, Korányi fasor 12, Szeged, 6720, Hungary. ., Markusovszky Teaching Hospital, Markusovszky str. 5, Szombathely, Hungary., Institute of Oncology, University of Debrecen, Nagyerdei krt. 98., Debrecen, Hungary., Faculty of Medicine, Department of Urology and Urooncological Centre, Semmelweis University, Üllői str. 78/b, Budapest, Hungary., Department of Oncotherapy, University of Szeged, Korányi fasor 12, Szeged, 6720, Hungary., Department of Oncology, Integrated St. Istvan and St. Laszlo Hospital, Albert Flórián str. 5-7, Budapest, Hungary., Faculty of Medicine, 1st Department of Internal Medicine, Division of Oncology, Semmelweis University, Tömő str.25-29, Budapest, Hungary., Institute of Oncotherapy, University of Pécs, Édesanyák 17., Pécs, Hungary., Institute of Radiotherapy and Clinical Oncology, Borsod County Hospital and University Academic Hospital, Szentpéteri Kapu 72-76, Miskolc, Hungary., National Institute of Oncology, Chemotherapy C and Clinical Pharmacology, Ráth György str. 7-9, Budapest, Hungary.